Several problems about the stereotactic body radiation therapy for lung cancer

Abstract

Su Chuanghuang, Li Derui. Several problems about the stereotactic body radiation therapy for lung cancer[J]. Journal of International Oncology, 2018, 45(3): 176-179.

［1］ Chang JY, Senan S, Paul MA, et al. Stereotactic ablative radiotherapy versus lobectomy for operable stage Ⅰ nonsmallcell lung cancer: a pooled analysis of two randomised trials［J］. Lancet Oncol, 2015, 16(6): 630-637. DOI: 10.1016/S1470-2045(15)70168-3. ［2］ Shibamoto Y, Hashizume C, Baba F, et al. Stereotactic body radiotherapy using a radiobiologybased regimen for stage Ⅰ nonsmall cell lung cancer［J］. 2012, 118(8): 2078-2084. DOI: 10.1002/cncr.26470. ［3］ Shirvani SM, Jiang J, Chang JY, et al. Comparative effectiveness of 5 treatment strategies for earlystage nonsmall cell lung cancer in the elderly［J］. Int J Radiat Oncol Biol Phys, 2012, 84(5): 1060-1070. DOI: 10.1016/j.ijrobp.2012.07.2354. ［4］ Miyazaki T, Yamazaki T, Nakamura D, et al. Surgery or stereotactic body radiotherapy for elderly stage Ⅰ lung cancer? A propensity score matching analysis［J］. Surg Today, 2017, 47(12): 1476-1483. DOI: 10.1007/s00595-017-1536-4. ［5］ Rosen JE, Salazar MC, Wang Z, et al. Lobectomy versus stereotactic body radiotherapy in healthy patients with stage Ⅰ lung cancer［J］. J Thorac Cardiovasc Surg, 2016, 152(1): 44-54, e9. DOI: 10.1016/j.jtcvs.2016.03.060. ［6］ Aoki M, Hatayama Y, Kawaguchi H, et al. Clinical outcome of stereotactic body radiotherapy for primary and oligometastatic lung tumors: a single institutional study with almost uniform dose with different five treatment schedules［J］. Radiat Oncol, 2016, 11: 5. DOI: 10.1186/s13014-016-0581-2. ［7］ Grills IS, Hope AJ, Guckenberger M, et al. A collaborative analysis of stereotactic lung radiotherapy outcomes for earlystage nonsmallcell lung cancer using daily online conebeam computed tomography imageguided radiotherapy［J］. J Thorac Oncol, 2012, 7(9): 1382-1393. DOI: 10.1097/JTO.0b013e318260e00d. ［8］ Chang JY, Li QQ, Xu QY, et al. Stereotactic ablative radiation therapy for centrally located early stage or isolated parenchymal recurrences of nonsmall cell lung cancer: how to fly in a "no fly zone"［J］. Int J Radiat Oncol Biol Phys, 2014, 88(5): 1120-1128. DOI: 10.1016/j.ijrobp.2014.01.022. ［9］ Chaudhuri AA, Tang C, Binkley MS, et al. Stereotactic ablative radiotherapy (SABR) for treatment of central and ultracentral lung tumors［J］. Lung Cancer, 2015, 89(1): 50-56. DOI: 10.1016/j.lungcan.2015.04.014. ［10］ Haseltine JM, Rimner A, Gelblum DY, et al. Fatal complications after stereotactic body radiation therapy for central lung tumors abutting the proximal bronchial tree［J］. Pract Radiat Oncol, 2016, 6(2): e27e33. DOI: 10.1016/j.prro.2015.09.012. ［11］ Bezjak A, Paulus R, Gaspar LE, et al. Efficacy and toxicity analysis of NRG Oncology/RTOG 0813 trial of stereotactic body radiation therapy (SBRT) for centrally located nonsmall cell lung cancer (NSCLC)［J］. Int J Radiat Oncol Biol Phys, 2016, 96 Suppl 2: S8. ［12］ Senthi S, Haasbeek CJ, Slotman BJ, et al. Outcomes of stereotactic ablative radiotherapy for central lung tumours: a systematic review［J］. Radiother Oncol, 2013, 106(3): 276-282. DOI: 10.1016/j.radonc.2013.01.004. ［13］ Tekatli H, Senan S, Dahele M, et al. Stereotactic ablative radiotherapy (SABR) for central lung tumors: plan quality and longterm clinical outcomes［J］. Radiother Oncol, 2015, 117(1): 64-70. DOI: 10.1016/j.radonc.2015.09.028. ［14］ Bezjak A, PaulusR, Gaspar LE, et al. Primary study endpoint analysis for NRG Oncology/RTOG 0813 trial of stereotactic body radiation therapy (SBRT) for centrally located nonsmall cell lung cancer (NSCLC)［J］. Int J Radiat Oncol Biol Phys, 2016, 94(1): 5-6. ［15］ Ghaye B, Wanet M, EI Hajjam M. Imaging after radiation therapy of thoracic tumors［J］. Diagn Interv Imaging, 2016, 97(10): 1037-1052. DOI: 10.1016/j.diii.2016.06.019. ［16］ Faruqi S, Giuliani ME, Raziee H, et al. Interrater reliability of the categorizationof late radiographic changes after lung stereotactic body radiation therapy［J］. Int J Radiat Oncol Biol Phys, 2014, 89(5): 1076-1083. DOI: 10.1016/j.ijrobp.2014.04.042. ［17］ Peulen H, Mantel F, Guckenberger M, et al. Validation of highrisk computed tomography features for detection of local recurrence after stereotactic body radiation therapy for earlystage nonsmall cell lung cancer［J］. Int J Radiat Oncol Biol Phys, 2016, 96(1): 134-141. DOI: 10.1016/j.ijrobp.2016.04.003. ［18］ Huang K, Senthi S, Palma DA, et al. Highrisk CT features for detection of local recurrence after stereotacticablative radiotherapy for lung cancer［J］. Radiother Oncol, 2013, 109(1): 51-57. DOI: 10.1016/j.radonc.2013.06.047. ［19］ Louie AV, Senan S, Dahele M, et al. Stereotactic ablative radiation therapy for subcentimeter lung tumors: clinical, dosimetric, and image guidance considerations［J］. Int J Radiat Oncol Biol Phys, 2014, 90(4): 843-849. DOI: 10.1016/j.ijrobp.2014.06.064. ［20］ Ricardi U, Frezza G, Filippi AR, et al. Stereotactic ablative radiotherapy for stage Ⅰ histologically proven nonsmall cell lung cancer: an Italian multicenter observational study［J］. Lung Cancer, 2014, 84(3): 248-253. DOI: 10.1016/j.lungcan.2014.02.015. ［21］ Loganadane G, Martinetti F, Mercier O, et al. Stereotactic ablative radiotherapy for early stage nonsmall cell lung cancer: a critical literature review of predictive factors of relapse［J］. Cancer Treat Rev, 2016, 50: 240-246. DOI: 10.1016/j.ctrv.2016.10.002. ［22］ Woody NM, Stephans KL, Marwaha G, et al. Stereotactic body radiation therapy for nonsmall cell lung cancer tumors greater than 5cm: safety and efficacy［J］. Int J Radiat Oncol Biol Phys, 2015, 92(2): 325-331. DOI: 10.1016/j.ijrobp.2015.01.045. ［23］ Marwaha G, Stephans KL, Woody NM, et al. Lung stereotactic body radiation therapy: regional nodal failure is not predicted by tumor size［J］. J Thorac Oncol, 2014, 9(11): 1693-1697. DOI: 10.1097/JTO.0000000000000313. ［24］ Kohutek ZA, Wu AJ, Zhang Z, et al. FDGPET maximum standardized uptake value is prognostic for recurrence and survival after stereotactic body radiotherapy for nonsmall cell lung cancer［J］. Lung Cancer, 2015, 89(2): 115-120. DOI: 10.1016/j.lungcan.2015.05.019. ［25］ Leeman JE, Rimner A, Montecalvo J, et al. Histologic subtype in core lung biopsies of earlystage lung adenocarcinoma is a prognostic factor for treatment response and failure patterns after stereotactic body radiation therapy［J］. Int J Radiat Oncol Biol Phys, 2017, 97(1): 138-145. DOI: 10.1016/j.ijrobp.2016.09.037.

[1]	Li Ping, Sun Xiaonan.Application of the combination of stereotactic body radiation therapy and immune checkpoint inhibitors in non-small cell lung cancer[J]. Journal of International Oncology, 2022, 49(2): 116-120.
[2]	Zhang Lili, Yu Yonghua.Research progress of stereotactic body radiation therapy for lung oligometastases of colorectal cancer[J]. Journal of International Oncology, 2020, 47(10): 630-633.
[3]	Cai Liang, Shen Yali. Application of stereotactic body radiation therapy in advanced renal cell carcinoma[J]. Journal of International Oncology, 2019, 46(10): 627-630.
[4]	Chen-Ya-Ping, JIANG Xiao-Xiao, JIANG Guan, FENG Shou-Xin.A Metaanalysis of transcatheter arterial chemoembolization comparing stereotactic body radiation therapy in patients for primary hepatic carcinoma[J]. Journal of International Oncology, 2015, 42(3): 182-187.
[5]	Lin Li, Zhou Fuxiang.Stereotactic body radiotherapy for early stage nonsmall cell lung cancer[J]. Journal of International Oncology, 2015, 42(10): 773-775.
[6]	LIN Gang, WANG Zhun, XU Ya-Ping.Application of stereotactic body radiotherapy in extracranial metastases[J]. Journal of International Oncology, 2014, 41(11): 820-823.

Several problems about the stereotactic body radiation therapy for lung cancer

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles6

Recommended Articles

Metrics

Comments